Sumitomo Pharma (4506) Q3 2025 earnings summary

Executive summary

• Returned to profitability in core operating profit, driven by 24.7% year-on-year revenue growth and significant cost reductions, especially in North America with strong sales of Orgovyx and Gemtesa.

• Net income turned positive, aided by a weaker yen, operational improvements, and effective cost management.

• Significant reduction in SG&A (down 29.6% YoY) and R&D expenses (down 48.0% YoY) due to restructuring and pipeline focus.

• Repayment date for bridge loan extended to March 2025, with ongoing refinancing discussions.

Financial highlights

• Q3 FY2024 revenue: ¥293.2B (up ¥58.2B YoY); gross profit: ¥179.7B (up ¥37.8B YoY).

• Core operating profit improved from a loss of ¥96.4B to a profit of ¥21.5B YoY; net profit attributable to owners: ¥21.2B, up ¥138.9B YoY.

• Cash and cash equivalents increased to ¥85.4B from ¥36.5B at prior year-end; operating cash flow improved from negative ¥230.7B to positive ¥5.5B YoY.

• SG&A and R&D expenses reduced by ¥52.2B and ¥32.6B, respectively.

• Deferred revenue from Myfembree recognized as a ¥9.1B lump sum.

Outlook and guidance

• Full-year revenue forecast raised to ¥381.0B; core operating profit forecast increased to ¥30.0B; net income forecast for FY2024: ¥16.0B.

• Key product sales forecasts revised upward, with Orgovyx at ¥78.5B and Gemtesa at ¥62.8B.

• ROE expected to improve to 9.8%; ROIC to 7.1%.

• Expect positive operating profit for the first time in several years.

• SG&A and R&D expenses to remain tightly managed; further cost reductions anticipated in Japan.